Establishment of the method for predicting clinical effect of tocilizumab based on its serum concentration in rheumatoid arthritis patients

Establishment of the method for predicting clinical effect of tocilizumab based on its serum concentration in rheumatoid arthritis patients - Establishment of the method for predicting clinical effect of tocilizumab based on its serum concentration in rheumatoid arthritis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041153

Enrollment

Registered

2020-07-19

Start date

2019-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients treated with intravenous or subcutaneous tocilizumab for rheumatoid arthritis 2. Patients receiving written informed consent

Exclusion criteria

Exclusion criteria: 1. Patients discontinuing tocilizumab. 2. Patients who are judged by physicians as inappropriate for study enrollment

Design outcomes

Primary

Measure	Time frame
Serum tocilizumab concentration before dosing by intravenous or subcutaneous injection	—

Countries

Japan

Contacts

Public ContactTakafumi Naito

Hamamatsu University School of Medicine Department of Hospital pharmacy

pharmacyham-adm@umin.ac.jp053-435-2763

Outcome results